The Multistrain Probiotic OMNi-BiOTiC® Active for Upper Respiratory Tract Infections in Older People
NCT ID: NCT05879393
Last Updated: 2023-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
95 participants
INTERVENTIONAL
2020-10-07
2022-07-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is the multistrain probiotic OMNi-BiOTiC® Active effective in reducing the incidence of URTIs in older people?
* Is the multistrain probiotic OMNi-BiOTiC® Active effective in reducing the duration of URTIs in older people?
* Is the multistrain probiotic OMNiBiOTiC® Active effective in changing selected immunological blood parameters in older people? Researchers will compare the probiotic group and the placebo group to see if the incidence or duration of URTIs are significant among the groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Probiotics on Symptoms of Upper Respiratory Tract Infections
NCT00599430
Clinical Trial to Evaluate the Efficacy of a Probiotic Preparation in the Prevention of Upper Respiratory Tract Infections in Adults
NCT07091955
Use of Probiotics to Prevent Influenza
NCT01720329
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
NCT05175833
The Effect of a Probiotic on Upper Respiratory Tract Infections
NCT03636191
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multistrain Probiotic OMNi-BiOTiC® Active
Lacticaseibacillus casei W56, Lactobacillus acidophilus W37, Ligilactobacillus salivarius W24, Levilactobacillus brevis W63, Lactococcus lactis W58, Lactococcus lactis W19, Bifidobacterium animalis subsp. lactis W52, Bifidobacterium longum subsp. longum W108, Bifidobacterium breve W25, Bifidobacterium animalis subsp. lactis W51 and Bifidobacterium bifidum W23. Additional ingredients:corn starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate and vanillin
OMNi-BiOTiC® Active
Multistrain probiotic
Placebo
rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
Placebo
rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OMNi-BiOTiC® Active
Multistrain probiotic
Placebo
rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ability of participant to eat independently
* ability of participant to adhere to all procedures of the clinical study
Exclusion Criteria
* participants experienced an exacerbation of metabolic diseases,
* participants with mental incapacity to understand instructions
* participants were prescribed long-term usage of antibiotics.
* participants that changed their eating habits or consumed any probiotics 14 days
* participants with markedly abnormal results of blood tests were excluded.
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Maribor
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sabina Fijan
Assoc. prof. dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sabina Fijan, Ph.D
Role: STUDY_DIRECTOR
University of Maribor, Faculty of Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Maribor, Faculty of Health Sciences
Maribor, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Strauss M, Micetic Turk D, Lorber M, Pogacar MS, Kozelj A, Tusek Bunc K, Fijan S. The Multi-Strain Probiotic OMNi-BiOTiC(R) Active Reduces the Duration of Acute Upper Respiratory Disease in Older People: A Double-Blind, Randomised, Controlled Clinical Trial. Microorganisms. 2023 Jul 5;11(7):1760. doi: 10.3390/microorganisms11071760.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMaribor
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.